ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2592

Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry

Herman F Mann1, Jakub Zavada2, Lucie Nekvindová3, Zlatuse Kristkova3, Pavel Horák4, Jiri Vencovsky1 and Karel Pavelka2, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, 4IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologics, psoriatic arthritis and registry

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A monoclonal antibody secukinumab (SEC) became available in March 2017. We aimed to characterize and compare patient populations starting treatment with SEC versus TNFi during the first year of SEC availability in Czech Republic.

Methods: All adult patients with PsA who either started biological therapy or switched to a new drug during the period of March 1st 2017 and March 1st 2018 were considered. Baseline characteristics of patients were described and compared between the two treatments. Mean ± SD and absolute/relative frequencies were used to describe continuous and categorical variables, respectively. P-value of Fisher‘s exact test and Mann-Whitney test is given when assessing difference between groups in categorical and continuous variables. Odds for the prescription of SEC versus TNFi were assessed using logistic regression. ATTRA is a computerized registry of patients receiving bDMARD therapy in the Czech Republic. Both TNFi and SEC is indicated for patients with PsA who have previously failed treatment with csDMARD. The choice of drug is left to the discretion of treating rheumatologist.

Results: A total of 243 bDMARD treatments were initiated or changed during the study period, 222 were included in the analysis (59 SEC, 163 TNFi). SEC was initiated as first line therapy in 47.5%, TNFi in 55.2% (P=0.361). Significant differences between SEC and TNFi were observed for some baseline patient characteristics (Table 1). Overall, patients starting SEC tended to have higher disease activity and worse measures of physical functioning. Patients after failure of 2 bDMARDs are 2.5 times more likely and after failure of ≥3 bDMARDs are 6.5 times more likely to receive SEC compared to patients starting their first line bDMARD (P<0.05). Odds of receiving SEC increase with increasing values of DAS28 (P = 0.003), SDAI (P = 0.014), and HAQ (P = 0.003) and decrease with higher scores of EUROQOL (p=0.002) and SF36 physical role functioning (P = 0.046), bodily pain (P = 0.004) and social role functioning (P = 0.040) domains. Baseline disease activity and physical functioning measures were not significantly different between SEC and TNFi among a subgroup of 118 patients (28 SEC, 90 TNFi,) receiving first line bDMARD.

Conclusion: Our data suggest that in real-life SEC is used as a first line bDMARD just as often as TNFi, however after failure of two or more bDMARDs patients are more likely to receive SEC. Overall patients starting SEC tend to have higher disease activity compared to patients starting TNFi.

Table 1: Selected baseline characteristics of patients starting SEC or TNFi treatment for PsA

Parameter

SEC

TNFi

P-value

Female gender, N (%)

31 (52.5%)

86 (52.8%)

1.000

Age in years, mean (±SD)

48.8 (9.0)

51.6 (11.6)

0.081

Disease duration in years, mean (±SD)

12.6 (9.0)

11.2 (7.9)

0.464

BMI, mean (±SD)

30.1 (6.5)

28.8 (5.2)

0.248

CRP in mg/dL, mean (±SD)

2.18 (2.38)

1.80 (2.55)

0.187

Presence of psoriasis, N (%)

36 (92.3%)

133 (91.1)

1.000

DAS28, mean (±SD)

5.0 (1.2)

4.2 (1.6)

0.004

SDAI, mean (±SD)

29.2 (13.3)

23.3 (15.1)

0.015

HAQ, mean (±SD)

1.4 (0.6)

1.1 (0.7)

0.005

EUROQOL, mean (±SD)

0.2 (0.3)

0.4 (0.4)

0.004

SF-36 social role functioning, mean (±SD)

43.4 (22.5)

50.9 (23.3)

0.039

SF-36 bodily pain, mean (±SD)

29.9 (15.4)

40.8 (24.9)

0.020

1st line bDMARD, N (%)

28 (47.5%)

90 (55.2%)

0.361

This study was supported by the project of MHCR for conceptual development of research organization 00023728


Disclosure: H. F. Mann, None; J. Zavada, None; L. Nekvindová, None; Z. Kristkova, None; P. Horák, None; J. Vencovsky, None; K. Pavelka, None.

To cite this abstract in AMA style:

Mann HF, Zavada J, Nekvindová L, Kristkova Z, Horák P, Vencovsky J, Pavelka K. Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/real-world-use-of-secukinumab-in-psoriatic-arthritis-first-year-data-from-the-czech-national-registry/. Accessed February 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-use-of-secukinumab-in-psoriatic-arthritis-first-year-data-from-the-czech-national-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.